文献速递心脑血管急症消化、代谢与肾脏急症

QT延长药物与尸检定义的心源性猝死病因风险的相关性

Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论在尸检确诊的猝死病例中,QT延长药物暴露与心律失常性猝死无关,而与尸检发现非心律失常性猝死风险增加相关。

该研究为前瞻性全县病例对照研究,纳入2011年2月1日至2014年3月1日旧金山县629例患者(525例疑似心源性猝死,104例创伤死亡对照)。通过处方清单和尸检毒理学计算QT延长药物暴露评分(0-20分)。结果显示,QT延长药物使用与疑似心源性猝死风险增加相关(低暴露OR 2.25,高暴露OR 6.70),但尸检裁定后,该风险仅与非心律失常性猝死相关(低风险OR 2.88,中风险OR 2.62,高风险OR 14.22),而与心律失常性猝死无关。提示基于共识标准的心源性猝死可能高估QT延长药物与心律失常性猝死的关联。

要点

  • 在525例疑似心源性猝死患者中,291例(55.4%)使用任何QT延长药物,显著高于创伤对照的28例(26.9%)(P<.001)。
  • QT延长药物使用与疑似心源性猝死风险增加相关:低暴露组OR 2.25(95%CI 1.03-4.96),高暴露组OR 6.70(95%CI 1.47-30.67)。
  • 尸检裁定后,QT延长药物使用与心律失常性猝死无显著关联,而与尸检定义的非心律失常性猝死风险增加相关:低风险OR 2.88(95%CI 1.18-6.99),中风险OR 2.62(95%CI 1.20-5.73),高风险OR 14.22(95%CI 2.91-69.30)。
  • 在最高暴露组中,排除隐匿性过量所致非心律失常性猝死后,上述关联减弱。
  • 使用共识标准定义心源性猝死的研究可能高估QT延长药物与心律失常性猝死的关联。

适用人群与场景

  • 纳入世界卫生组织定义的疑似心源性猝死并接受尸检的病例,以及因创伤死亡的对照,来自2011年2月1日至2014年3月1日旧金山县的POST SCD研究。

诊断标准与关键阈值

  • QT延长药物暴露评分范围为0-20分,1分为低暴露,2-4分为中等暴露,>4分为高暴露。

研究设计与关键结果

  • 研究类型为前瞻性全县病例对照研究,共纳入629例患者(平均[SD]年龄61.4[15.7]岁;439例男性[69.8%]),其中525例疑似心源性猝死,104例创伤死亡对照。
  • 疑似心源性猝死患者QT延长药物暴露更高,291例(55.4%)使用任何QT延长药物,而创伤对照为28例(26.9%)(P<.001)。
  • QT延长药物使用与疑似心源性猝死风险增加相关:低暴露组OR 2.25(95%CI 1.03-4.96;P=.04),高暴露组OR 6.70(95%CI 1.47-30.67;P=.01)。
  • 尸检裁定后,QT延长药物使用与心律失常性猝死无显著关联,而与尸检定义的非心律失常性猝死风险增加相关:低风险OR 2.88(95%CI 1.18-6.99;P=.02),中风险OR 2.62(95%CI 1.20-5.73;P=.02),高风险OR 14.22(95%CI 2.91-69.30;P=.001)。
  • 在最高暴露组中,排除隐匿性过量所致非心律失常性猝死后,QT延长药物与非心律失常性猝死的关联减弱。

证据类型、等级与局限

  • 证据类型为前瞻性病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,使用共识标准定义心源性猝死的研究可能高估QT延长药物与心律失常性猝死的关联。
  • 尸检裁定后,QT延长药物暴露与心律失常性猝死无显著关联,而与尸检定义的非心律失常性猝死风险增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: QT-prolonging medications (QTPMs) are a reported risk factor for sudden cardiac death (SCD) when defined by consensus criteria that presume an arrhythmic cause. The effect of QTPM on autopsy-defined sudden arrhythmic death (SAD) is unknown.

OBJECTIVE: To evaluate the association between QTPM and autopsy-defined SAD vs nonarrhythmic cause of sudden death.

DESIGN, SETTING, AND PARTICIPANTS: This prospective countywide case-control study included World Health Organization-defined (presumed) SCD cases who underwent autopsy as part of the San Francisco Postmortem Systematic Investigation of Sudden Cardiac Death Study (POST SCD) to determine arrhythmic or nonarrhythmic cause, and control deaths due to trauma (hereinafter referred to as trauma controls) in San Francisco County, California, from February 1, 2011, to March 1, 2014. Multivariate regression was used to evaluate the association of QTPM with the risk of presumed SCD, autopsy-defined SAD, and non-SAD compared with trauma controls. Medication exposure, determined by prescription lists and postmortem toxicologic findings, was used to calculate a summative QTPM exposure score (range, 0-20). Data were analyzed from September 1, 2018, to June 15, 2019.

EXPOSURE: QT-prolonging medication exposure, as measured by QTPM score (1 indicated low; 2-4, moderate; and >4, high).

MAIN OUTCOMES AND MEASURES: Death due to trauma, presumed SCD, and autopsy-defined non-SAD and SAD with no postmortem findings of extracardiac cause.

RESULTS: A total of 629 patients (mean [SD] age, 61.4 [15.7] years; 439 men [69.8%]) were included, 525 with presumed SCDs and 104 traumatic death controls. Individuals with presumed SCDs had higher exposure and were more likely to be taking any QTPM (291 [55.4%] vs 28 [26.9%]; P < .001) than trauma controls. Use of QTPMs was associated with increased risk of presumed SCD in low (odds ratio [OR], 2.25 [95% CI, 1.03-4.96]; P = .04) and high (OR, 6.70 [95% CI, 1.47-30.67]; P = .01) exposure groups. After autopsy adjudication, use of QTPMs was associated with increased risk of non-SAD (low-risk OR, 2.88 [95% CI, 1.18-6.99; P = .02]; moderate-risk OR, 2.62 [95% CI, 1.20-5.73; P = .02]; and high-risk OR, 14.22 [95% CI, 2.91-69.30; P = .001]) but not SAD in all exposure groups. This association was attenuated by the exclusion of occult overdose non-SADs in the highest exposure group.

CONCLUSIONS AND RELEVANCE: These findings confirm the association between QTPMs and presumed SCD; however, after autopsy, this risk was specific for nonarrhythmic causes of sudden death. Studies using consensus SCD criteria may overestimate the association of QTPMs with the risk of SAD.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Simpson TF, Salazar JW, Vittinghoff E, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Intern Med. 2020. PMID: 32119028. doi:10.1001/jamainternmed.2020.0148

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。